Literature DB >> 16181417

Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers.

Guylaine Hoffner1, Marie-Laure Island, Philippe Djian.   

Abstract

Huntington's disease resulting from huntingtin containing an expanded polyglutamine is associated with aggregates largely confined to neuronal inclusions, and with neuronal death. Inclusions are thought to originate from discrete N-terminal fragments of expanded huntingtin produced by specific endopeptidases. We have now purified the neuronal inclusions of Huntington's disease brain. When incubated in concentrated formic acid, purified inclusions release a polymer, an oligomer and a broad range of N-terminal fragments of expanded huntingtin. The fragments and the polymeric forms are linked to each other by non-covalent bonds as they are both released by formic acid, whereas the polymeric forms themselves are presumably stabilized by covalent bonds, as they are resistant to formic acid. We also demonstrate the presence in affected areas of the brain but not in unaffected areas of a broad range of soluble N-terminal fragments of expanded huntingtin not yet associated with the inclusions and which are likely to be the precursors of the inclusions. Fragmentation of expanded huntingtin in Huntington's disease must result from the operation of multiple proteolytic activities with little specificity and not from that of a specific endopeptidase; subsequent aggregation of the fragments by covalent and non-covalent bonds leads to the formation of the inclusions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181417     DOI: 10.1111/j.1471-4159.2005.03348.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

1.  Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.

Authors:  E L Scotter; C E Goodfellow; E S Graham; M Dragunow; M Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.

Authors:  James R Arndt; Maxmore Chaibva; Justin Legleiter
Journal:  Biomol Concepts       Date:  2015-03

Review 3.  Protein aggregates in Huntington's disease.

Authors:  Montserrat Arrasate; Steven Finkbeiner
Journal:  Exp Neurol       Date:  2011-12-19       Impact factor: 5.330

4.  The folding equilibrium of huntingtin exon 1 monomer depends on its polyglutamine tract.

Authors:  Jose M Bravo-Arredondo; Natalie C Kegulian; Thomas Schmidt; Nitin K Pandey; Alan J Situ; Tobias S Ulmer; Ralf Langen
Journal:  J Biol Chem       Date:  2018-10-12       Impact factor: 5.157

Review 5.  Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?

Authors:  Guylaine Hoffner; Philippe Djian
Journal:  Mol Neurobiol       Date:  2014-10-22       Impact factor: 5.590

Review 6.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

7.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

8.  Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding.

Authors:  Maxmore Chaibva; Sudi Jawahery; Albert W Pilkington; James R Arndt; Olivia Sarver; Stephen Valentine; Silvina Matysiak; Justin Legleiter
Journal:  Biophys J       Date:  2016-07-26       Impact factor: 4.033

Review 9.  Neuroprotection for Huntington's disease: ready, set, slow.

Authors:  Steven M Hersch; H Diana Rosas
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

10.  Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.

Authors:  Joonil Jung; Kexiang Xu; Derek Lessing; Nancy M Bonini
Journal:  Hum Mol Genet       Date:  2009-09-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.